All In Biotech

Drug Trial Radar · NCT06982521

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

A Phase 3 Open-Label Randomized Study Assessing the Efficacy and Safety of RLY-2608 + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for PIK3CA-mutant Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Locally Advanced or Metastatic Breast Cancer Following Recurrence or Progression On or After Treatment With a CDK4/6 Inhibitor

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 540 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

540

Planned (sponsor's estimate)

Start

Aug 26, 2025

Primary completion

Apr 30, 2028

Study completion Dec 31, 2031

Sponsor

Lead sponsor
Relay Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
May 21, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global, multicenter, open-label, randomized Phase 3 study comparing the efficacy and safety of RLY-2608 (zovegalisib) + fulvestrant to capivasertib + fulvestrant for the treatment of patients with HR+/HER2- ABC with PIK3CA mutation following recurrence or progression on or after treatment with a CDK4/6 inhibitor.

Conditions

  • PIK3CA Mutation
  • HER2- Negative Breast Cancer
  • Hormone Receptor Positive Tumor
  • Breast Cancer
  • Metastatic Breast Cancer
  • Advanced Breast Cancer

Interventions

  • ZovegalisibDrug

    400 mg orally BID administered daily on a 28-day treatment cycle

  • CapivasertibDrug

    400mg orally BID administered on an intermittent weekly dosing schedule. Patients will dose on Days 1 through 4 each week of a 28-day treatment cycle

  • FulvestrantDrug

    500 mg intramuscularly administered on Cycle 1 Day 1, Day 15, and Day 1 of each subsequent cycle (28-day treatment cycle)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR)Time frame: The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months

Locations

254 sites in 27 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • Beverly Hills Cancer Center

    Beverly Hills, California · Recruiting

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California · Recruiting

  • Stanford Women's Cancer Center

    Palo Alto, California · Recruiting

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of California San Diego Moores Cancer Center

    San Diego, California · Recruiting

  • University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, California · Recruiting

  • Kaiser Permanente Medical Center

    Vallejo, California · Recruiting

  • Rocky Mountain Cancer Centers, LLP

    Longmont, Colorado · Recruiting

  • Yale-New Haven Hospital-Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Medical Oncology Hematology Consultants, P.A.

    Newark, Delaware · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • AdventHealth

    Altamonte Springs, Florida · Recruiting

  • Florida Cancer Specialists-South

    Fort Myers, Florida · Recruiting

  • Cancer Care Centers of Brevard, Inc

    Palm Bay, Florida · Recruiting

  • Atlanta Cancer Care - Northside Hospital

    Atlanta, Georgia · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University

    Chicago, Illinois · Recruiting

  • Community Health Network, Inc

    Indianapolis, Indiana · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Cancer Center of Kansas

    Wichita, Kansas · Recruiting

  • Sidney Kimmel Comprehensive Cancer Center (SKCCC) at Johns Hopkins

    Baltimore, Maryland · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • University of Michigan

    Ann Arbor, Michigan · Recruiting

  • Profound Research LLC

    Royal Oak, Michigan · Recruiting

  • Minnesota Oncology Hematology, P.A.

    Minneapolis, Minnesota · Recruiting

  • University of Mississippi Medical Center

    Jackson, Mississippi · Recruiting

  • Washington University School of Medicine- Siteman Cancer Center

    St Louis, Missouri · Recruiting

  • Nebraska Cancer Specialists

    Omaha, Nebraska · Recruiting

  • Renown Health Medical Oncology

    Reno, Nevada · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute

    New Brunswick, New Jersey · Recruiting

  • Laura and Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai

    New York, New York · Recruiting

  • Columbia University Irving Medical Center

    New York, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Oregon Health & Science University, Knight Cancer Institute

    Portland, Oregon · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

Showing 40 of 254 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.